文献速递乳腺MR

动态增强MRI中乳腺纤维腺体组织强化速率反映新辅助治疗反应

The rate of breast fibroglandular enhancement during dynamic contrast-enhanced MRI reflects response to neoadjuvant therapy.
PubMed 文献 · Eur J Radiol · 2021-01-09

本研究纳入19例局部晚期乳腺癌女性,在新辅助治疗(NAT)全程行4次动态增强MRI(时间分辨率7.27秒),半自动分割肿瘤与纤维腺体组织并计算强化速率。纤维腺体组织强化速率在NAT全程平均下降29%(19例中16例出现下降),且达到病理完全缓解(pCR)者在1周期后(高68%,p<0.05)和3-5周期后(高58%,p<0.05)强化速率均显著更高;结论认为该指标随治疗下降、提供肿瘤指标未反映的信息,并可能早期预测病理反应,反应良好者强化下降幅度更小。

要点

  • 纤维腺体组织强化速率在NAT全程平均下降29%,19例中16例出现下降。
  • 达到pCR者纤维腺体强化速率在1周期后高68%(p<0.05)、3-5周期后高58%(p<0.05)。
  • 纤维腺体强化相对强度与强化速率相关(R2=0.64,p<0.001),pCR者在两时间点均更高(p<0.05)。

核心结论

  • 纤维腺体组织强化速率随NAT下降,提供肿瘤指标未反映的新信息,并可能早期预测病理反应,反应良好者强化下降幅度更小。

研究设计与样本

  • 研究纳入19例局部晚期乳腺癌女性,在NAT全程共行4次动态增强MRI,钆对比剂注射后采集,时间分辨率7.27秒。
  • 以手动勾画包含肿瘤的感兴趣区后经模糊C均值聚类半自动分割肿瘤、纤维腺体组织和脂肪组织,逐体素计算强化速率与信号强化相对强度。

关键影像表现/征象

  • 纤维腺体组织强化速率在NAT全程平均下降29%,19例中16例出现该下降。

诊断标准与关键数值

  • pCR者纤维腺体组织强化速率在1周期NAT后高68%(p<0.05),在3-5周期后高58%(p<0.05)。
  • 纤维腺体强化相对强度与强化速率相关(R2=0.64,p<0.001),且在1周期后与3-5周期后两个时间点pCR者均更高(p<0.05)。

临床应用与阅片要点

  • 阅片时可关注纤维腺体组织强化速率随NAT的变化,结合肿瘤指标综合评估治疗反应。
  • 原文结论为可能早期预测病理反应,pCR者强化下降幅度更小,尚需进一步研究。

局限性

  • 原文结论提出该指标可能预测病理反应,并指出需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study assesses the rate of enhancement of breast fibroglandular tissue after administration of a magnetic resonance imaging (MRI) gadolinium-based contrast agent and determines its relationship with response to neoadjuvant therapy (NAT) in women with breast cancer.

METHOD: Women with locally advanced breast cancer (N = 19) were imaged four times over the course of NAT. Dynamic contrast-enhanced (DCE) MRI was acquired after administration of a gadolinium-based contrast agent with a temporal resolution of 7.27 s. The tumor, fibroglandular tissue, and adipose tissue were semi-automatically segmented using a manually drawn region of interest encompassing the tumor followed by fuzzy c-means clustering. The rate and relative intensity of signal enhancement were calculated for each voxel within the tumor and fibroglandular tissue.

RESULTS: The rate of fibroglandular tissue enhancement after contrast agent injection declined by an average of 29 % over the course of NAT. This decline was present in 16 of the 19 patients in the study. The rate of enhancement is significantly higher in women who achieve pathological complete response (pCR) after both 1 cycle (68 % higher, p < 0.05) and after 3-5 cycles of NAT (58 % higher; p < 0.05). The relative intensity of fibroglandular enhancement correlates with the rate of enhancement (R2 = 0.64, p < 0.001) and is higher in women who achieve pCR after both 1 cycle and after 3-5 cycles of NAT (p < 0.05, both timepoints).

CONCLUSION: The rate of fibroglandular tissue enhancement declines over the course of therapy, provides novel information not reflected by tumoral measures, and may predict pathological response early in the course of therapy, with smaller declines in enhancement in women who achieve favorable response.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Virostko J, Kuketz G, Higgins E, et al. The rate of breast fibroglandular enhancement during dynamic contrast-enhanced MRI reflects response to neoadjuvant therapy. Eur J Radiol. 2021. PMID: 33454460. doi:10.1016/j.ejrad.2021.109534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。